A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

Phase 2

Terminated

• Conditions: Liver Cancer; Hepatocellular Cancer
• Interventions: Drug: Oxaliplatin; Drug: Capecitabine

• Registration Number: NCT03026803
• Lead Sponsor: City of Hope Medical Center

Brief Summary

This phase II trial is studying how well giving oxaliplatin and capecitabine together works in treating patients with liver cancer.

Detailed Description

Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving these drugs together may kill more tumor cells.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2006-11
• Primary Completion: 2014-10
• Study Completion: 2014-10
• Study First Submitted: 2017-01-17
• Study First Submitted QC: 2017-01-18
• Results First Submitted: 2017-01-19
• Results First Submitted QC: 2017-01-19
• Study First Posted: 2017-01-20
• Status Verified: 2017-03
• Results First Posted: 2017-03-10
• Last Update Submitted: 2017-03-16
• Last Update Posted: 2017-04-13

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Patients must have histologically confirmed hepatocellular carcinoma which is recurrent, metastatic or unresectable.
• Patients may have up to two prior chemotherapy regimes. In addition, they may have had previous radiation, chemoembolization, and/or alcohol injections.
• Patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, and which has clearly progressed during the observation interval prior to participation in this study. Pleural effusions and ascites will not be considered measurable, but may be present in addition to the measurable lesion(s).
• Karnofsky performance status > 70%.
• Patients should have an expected survival of at least 2 months.
• Leukocytes >3,000/µl
• Absolute neutrophil count >1,500/µl
• Platelets >50,000/µl
• Total bilirubin < 3.0 g/dl
• AST (aspartate aminotransferase) (serum glutamic oxaloacetic transaminase(SGOT)/ALT (alanine aminotransferase) (serum glutamic pyruvic transaminase)(SGPT) < 5 times institutional upper limit of normal
• Creatinine < 2.0 OR measured or calculated creatinine clearance >60 mL/min for patients with creatinine levels above institutional normal
• Brain metastasis is not an exclusion, however, patients are only eligible if they have had successful control of the brain tumor(s) by surgery or stereotactic RT.
• Patients with no evidence of clinically significant neuropathy.
• All prior therapy must have been completed at least 4 weeks prior to the patient's entry on this trial.
• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Breastfeeding should be discontinued if the mother is treated with oxaliplatin.
• Subjects with chronic hepatitis B or C may be undergoing treatment with α interferon and/or ribavirin, as long as they meet the other criteria for entry on to this study.
• Ability to understand and the willingness to sign a written informed consent document.

Read More

Exclusion Criteria

• Patients have prior oxaliplatin or xeloda treatment or undergoing therapy with other investigational agents.
• History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy.
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, or unstable angina pectoris, or cardiac arrhythmia.
• HIV-positive patients receiving anti-retroviral therapy (HAART) are excluded from the study because of possible pharmacokinetic interactions.
• Patients with a diagnosis of pulmonary fibrosis or a pulmonary interstitial process.
• Patients unable to swallow capecitabine will be excluded from this study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Oxaliplatin and Capecitabine	Oxaliplatin	21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
Oxaliplatin and Capecitabine	Capecitabine	21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14

Primary Outcome Measures

Name	Time	Method
Response Rate	Up to 2 years	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Trial Locations

Locations (1)

City of Hope Medical Center; 🇺🇸 Duarte, California, United States